. In this report, we have studied the anti-inflammatory properties of the reference A 2A agonist CGS-21680, given intranasally at doses of 10 and 100 g/kg, in a variety of murine models of asthma and COPD. After an acute ovalbumin challenge of sensitized mice, prophylactic administration of CGS-21680 inhibited the bronchoalveolar lavage fluid inflammatory cell influx but not the airway hyperreactivity to aerosolized methacholine. After repeated ovalbumin challenges, CGS-21680 given therapeutically inhibited the bronchoalveolar lavage fluid inflammatory cell influx but had no effect on the allergen-induced bronchoconstriction, the airway hyperreactivity, or the bronchoalveolar lavage fluid mucin levels. As a comparator, budesonide given intranasally at doses of 0.1-1 mg/kg fully inhibited all the parameters measured in the latter model. In a lipopolysaccharide-driven model, CGS-21680 had no effect on the bronchoalveolar lavage fluid inflammatory cell influx or TNF-␣, keratinocyte chemoattractant, and macrophage inflammatory protein-2 levels, but potently inhibited neutrophil activation, as measured by bronchoalveolar lavage fluid elastase levels. With the use of a cigarette smoke model of lung inflammation, CGS-21680 did not significantly inhibit bronchoalveolar lavage fluid neutrophil infiltration but reversed the cigarette smoke-induced decrease in macrophage number. Together, these results suggest that activation of the A 2A receptor would have a beneficial effect by inhibiting inflammatory cell influx and downregulating inflammatory cell activation in asthma and COPD, respectively. chronic obstructive pulmonary disorder therapies; anti-asthmatic agents; animal models ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are chronic inflammatory disorders of the airways. Asthma is characterized by infiltration of the lung with inflammatory cells such as eosinophils and lymphocytes, mucus hypersecretion, and by the presence of bronchial hyperresponsiveness to a variety of stimuli (26). COPD is characterized by slowly progressive and irreversible airway obstruction, mucus hypersecretion, and infiltration of activated neutrophils and macrophages into the lungs (24). Adenosine is a purine nucleoside that is released during tissue hypoxia, and inflammation and has both pro-and anti-inflammatory roles mediated by four different G protein-coupled receptors, A 1 (G i coupled), A 2A (G s coupled), A 2B (G s and G q11 coupled), and A 3 (G s and G q11 coupled). Each receptor can be implicated either beneficially and/or detrimentally in the development of inflammation. However, a lot of evidence points toward a predominant role for the A 2A receptor subtype in the anti-inflammatory activities of adenosine. As such, specific activation of the A 2A receptor with agents such as CGS-21680 or ATL-146e has demonstrated anti-inflammatory activities in animal models of septic arthrosis (6), reperfusion injury (3, 11, 31) , and bacterial meningitis (37). In addition, the use of A 2A receptor-deficient mice has clearly demonstrated a nonredundant role for this receptor in downregulating ongoing inflammation (30). Despite the fact that A 2A receptor activation has been postulated as a way to downregulate inflammation in airway diseases such as asthma and COPD (16, 28, 36) , only one animal study has addressed this question and demonstrated that activation of the A 2A receptor with CGS-21680 reduces inflammatory cell infiltration in a Brown Norway rat model of asthma (15). However, in this work the authors did not study the effect of the compound on airway hyperreactivity and mucin production, two cardinal features of asthma. In addition, no data are available from animal models of COPD that would support the concept of a beneficial effect of an A 2A receptor agonist in this disease.
ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are chronic inflammatory disorders of the airways. Asthma is characterized by infiltration of the lung with inflammatory cells such as eosinophils and lymphocytes, mucus hypersecretion, and by the presence of bronchial hyperresponsiveness to a variety of stimuli (26) . COPD is characterized by slowly progressive and irreversible airway obstruction, mucus hypersecretion, and infiltration of activated neutrophils and macrophages into the lungs (24) . Adenosine is a purine nucleoside that is released during tissue hypoxia, and inflammation and has both pro-and anti-inflammatory roles mediated by four different G protein-coupled receptors, A 1 (G i coupled), A 2A (G s coupled), A 2B (G s and G q11 coupled), and A 3 (G s and G q11 coupled). Each receptor can be implicated either beneficially and/or detrimentally in the development of inflammation. However, a lot of evidence points toward a predominant role for the A 2A receptor subtype in the anti-inflammatory activities of adenosine. As such, specific activation of the A 2A receptor with agents such as CGS-21680 or ATL-146e has demonstrated anti-inflammatory activities in animal models of septic arthrosis (6) , reperfusion injury (3, 11, 31) , and bacterial meningitis (37) . In addition, the use of A 2A receptor-deficient mice has clearly demonstrated a nonredundant role for this receptor in downregulating ongoing inflammation (30) . Despite the fact that A 2A receptor activation has been postulated as a way to downregulate inflammation in airway diseases such as asthma and COPD (16, 28, 36) , only one animal study has addressed this question and demonstrated that activation of the A 2A receptor with CGS-21680 reduces inflammatory cell infiltration in a Brown Norway rat model of asthma (15) . However, in this work the authors did not study the effect of the compound on airway hyperreactivity and mucin production, two cardinal features of asthma. In addition, no data are available from animal models of COPD that would support the concept of a beneficial effect of an A 2A receptor agonist in this disease.
In this study, we have used CGS-21680 (10) to delineate the potential anti-inflammatory role of the adenosine A 2A receptor in two different allergen-driven murine models of asthma characterized by inflammatory cell infiltration, airway hyperreactivity and mucin secretion. The effect of CGS-21680 was also studied in murine COPD-related models, i.e., lipopolysaccharide-driven models of airway neutrophilic infiltration and activation and a model of cigarette smoke-induced lung inflammation.
MATERIALS AND METHODS
Materials. All materials were obtained from Sigma-Aldrich (Gillingham, UK) unless specified otherwise.
Animals. Eight-week-old female BALB/c mice (Charles River, Margate, UK) were acclimatized for a period of at least 7 days upon arrival before any experimental work began. The studies conformed to the United Kingdom Animals (scientific procedures) Act of 1986 and were approved by the institutional review board.
Ovalbumin models of allergic lung inflammation. CGS-21680 was given prophylactically in an acute challenge model (41) and given therapeutically in a repeated challenge model (5) . Briefly, mice were immunized intraperitoneally with 10 (acute model) or 20 (repeated model) g of ovalbumin in Alum (0.2 ml) on days 0 and 14. For the acute model, animals were exposed for 20 min to an aerosol of 5% ovalbumin on day 21 . For the repeated model, animals were exposed for 20 min to an aerosol of 1% ovalbumin on days 21, 22 , and 23 and to an aerosol of 5% ovalbumin on day 26. Control animals were immunized with ovalbumin and challenged with the ovalbumin vehicle, PBS.
Lipopolysaccharide models of neutrophilic lung infiltration and activation. To study airway neutrophil infiltration, mice were challenged intranasally, under halothane/oxygen/nitrous oxide anesthesia, with 0.3 mg/kg of lipopolysaccharide or its vehicle (PBS, 50 l). To study neutrophil activation, airway neutrophilia was established as described above. Twenty-four hours later, N-formyl-Met-Leu-Phe (fMLP, 5 mg/kg) or its vehicle (50 l of 1% DMSO in PBS) was applied intranasally, and the mice were killed 2 h thereafter (8) .
Cigarette smoke model of lung inflammation. Mice were exposed to tobacco smoke generated from five cigarettes (2R4F research cigarette; Univ. of Kentucky, Louisville, KY) or air on three consecutive days as described previously for rats (35) and killed 24 h after the last exposure.
Lung function measurement. Lung function changes [enhanced pause (Penh)] were measured using barometric plesythmography and whole body plesythmography (Buxco Electronics, Sharon, CT). The allergen-induced bronchoconstriction in the chronic model was measured for 5 min, 4 h after the end of the last challenge, and baseline respiratory parameters were measured for 5 min, just before the last allergen challenge. Airway reactivity to aerosolized methacholine was measured 24 h after the last allergen challenge (41) .
Determination of bronchoalveolar lavage parameters. At the indicated time point, terminal anesthesia was induced, and bronchoalveolar lavage and differential cell counts were performed as described previously (41) . Bronchoalveolar lavage fluid supernatants were assayed for neutrophil elastase activity and mucin level as previously described by our group. Neutrophil elastase activity was measured using the fluorogenic substrate (Me-Suc-Ala-Ala-Pro-Val-MCA; Bachem, Weil am Rhein, Germany). Samples and standard human neutrophil elastase were incubated with the substrate at 37°C, and the cleavage of the substrate was measured using a fluorometer set at 370 nm excitation and 460 nm emission (8) . Mucin levels were determined by a mucin enzyme-linked lectin assay. Samples and purified human mucin standard (Novartis, Horsham, UK) were added to Ulex europaeus agglutinin-1 (UEA-1)-precoated wells. After a 1-h incubation at 37°C, horseradish peroxidase-conjugated UEA-1 was added for 1.5 h, followed by addition of the substrate (orthophenyldiamine dihydrochloride). The reaction was stopped by addition of 4 M H 2SO4 (2) .
Drug treatment. Mice were treated via the intranasal route, under halothane/oxygen/nitrous oxide anesthesia, with CGS-21680 or budesonide in PBS containing 2% DMSO. Control mice received 50 l of vehicle (41) . The dose range selected was based on previous in vivo studies (9, 15) . The treatment schedule is detailed in RESULTS.
Data analysis. Whenever possible, the dose that induced 50% inhibition of the signal (ED 50) was calculated by fitting a sigmoidal curve to the dose-response data (i.e., 2 doses and the positive and negative control groups). Data are expressed as means Ϯ SE, and statistical significance (P Ͻ 0.05) was determined using the MannWhitney test with Bonferroni correction for multiple comparison.
RESULTS
Effect of CGS-21680, given prophylactically, in the acute ovalbumin model of allergic lung inflammation. We first studied the prophylactic effect of CGS-21680 given half an hour before and 3 h after a single ovalbumin challenge. When compared with sensitized and PBS-challenged mice, mice challenged with ovalbumin had an increased bronchoconstrictor response to aerosolized methacholine measured 24 h postchallenge. CGS-21680, given prophylactically at doses of 10 and 100 g/kg, had no effect on the ovalbumin-induced airway hyperreactivity to aerosolized methacholine (Fig. 1A) . We have previously shown that budesonide is fully effective in inhibiting the airway hyperreactivity to aerosolized methacholine in this model (9) .
Immediately after completion of the airway reactivity measurement, mice were killed and bronchoalveolar lavage was performed. When compared with the PBS-challenged animals, there were significant increases in the numbers of neutrophils, eosinophils, macrophages, and lymphocytes recovered in the bronchoalveolar lavage fluid. CGS-21680 dose dependently inhibited all inflammatory cell influx except the macrophage (Fig. 1B) . Its effect was ϳ10 times more potent than budesonide (Table 1) . No significant increase in the bronchoalveolar lavage fluid mucin levels could be detected (0 and 0.5 Ϯ 0.3 U/ml for the PBS-and ovalbumin-challenged animals, respectively; P ϭ 0.18), and therefore the effect of CGS-21680 or budesonide on this parameter could not be studied. Fig. 1 . Effect of CGS-21680, given prophylactically, on airway hyperreactivity to methacholine (A) and bronchoalveolar lavage (BAL) fluid cellular inflammation (B) after a single ovalbumin challenge. Sensitized mice were either challenged with an aerosol of PBS or 5% ovalbumin. Animals were intranasally treated with 10 or 100 g/kg of CGS-21680 or its vehicle half an hour before and 3 h after the challenge. Twenty-four hours after the last challenge, animals were placed in the plesythmography box and sequentially exposed to increasing concentrations of aerosolized methacholine (0 -0.3 M) for 2 min. Enhanced pause (Penh) was measured for 5 min after each nebulization. Immediately after the measurement of the airway response, BAL was performed, and differential inflammatory cell counts were determined. AUC; area under the curve. Significance (*P Ͻ 0.05) is vs. vehicle-treated/ ovalbumin-challenged animals (ovalbumin). Results are expressed as means Ϯ SE from 8 mice/group.
Effect of CGS-21680 and budesonide, given therapeutically, in the repeated ovalbumin challenge model of allergic lung inflammation.
We next studied the effect of therapeutic dosing with CGS-21680 against ovalbumin-induced lung inflammation. To do so, animals were challenged with ovalbumin for three consecutive days to establish a baseline inflammation. Two days after the third challenge, animals were either exposed to PBS (OA/PBS) or ovalbumin (OA/OA). Control animals were exposed four times to PBS (PBS/PBS). CGS-21680 (10 or 100 g/kg) was given twice daily starting 30 min before the last ovalbumin challenge. Four hours after the last challenge, no bronchoconstriction was observed in the PBS/ PBS or the OA/PBS groups. In contrast, animals challenged four times with ovalbumin developed a bronchoconstriction, and CGS-21680 had no effect on this phenomenon ( Fig. 2A,  left) . Although markedly attenuated, the bronchoconstriction observed in the OA/OA group was still present 24 h after the challenge as shown by the significant increase in baseline Penh when compared with the PBS/PBS and OA/PBS groups (Fig.  2B, left) . No difference in the airway reactivity to aerosolized methacholine, measured 24 h after the last challenge, was observed between the PBS/PBS and OA/PBS groups. When compared with the OA/OA group, animals treated with 100 g/kg of CGS-21680 had a twofold increase in the baseline Penh value and an increased sensitivity to the two lower doses of aerosolized methacholine (Fig. 2B, left) .
Forty-eight hours after the last challenge, macrophages were the predominant cell type found in the bronchoalveolar lavage fluids of the PBS/PBS group. As expected, when compared with the PBS/PBS group, the airway inflammatory cell numbers (i.e., neutrophil, eosinophil, macrophages, and lymphocytes) were increased in the OA/PBS group and further increased in the OA/OA group. Although CGS-21680 dose dependently inhibited all inflammatory cell influx (Fig. 2C,  left) , it was less potent when compared with the acute challenge model. However, it was still more potent than budesonide (Table 1) .
Forty-eight hours after the last challenge, mucin could be detected in the bronchoalveolar lavage fluid of the OA/PBS group, and the last ovalbumin challenge induced a further fivefold increase in mucin levels (OA/OA group). A small inhibition of the mucin production was observed in animals treated with both doses of CGS-21680. However, this was not significant and no dose relationship was observed. No mucin were detected in the bronchoalveolar lavage fluids from the PBS/PBS animals (Fig. 2D, left) .
When given therapeutically once a day starting 1 h before the last challenge, budesonide dose dependently inhibited the allergen-induced bronchoconstriction ( Fig. 2A, right) , the airway hyperreactivity to aerosolized methacholine (Fig. 2B,  right) , the bronchoalveolar lavage fluid cell influx (Fig. 2C,  right) , and the increased mucin levels (Fig. 2D, right) . For all these parameters, budesonide had an ED 50 of 100 -300 g/kg ( Table 1) .
Effect of CGS-21680 in the lipopolysaccharide model of neutrophilic lung inflammation. Three hours after the challenge, lipopolysaccharide increased the number of bronchoalveolar lavage fluid neutrophils and to a lesser extent the number of lymphocytes. At that time point, the macrophage numbers were decreased by lipopolysaccharide, probably reflecting their activation status (Fig. 3A, left) . Twenty-four hours postchallenge, lipopolysaccharide increased the number of bronchoalveolar lavage fluid neutrophils, macrophages, and lymphocytes (Fig. 3B, left) . At the 3-h time point, in animals treated with CGS-21680, there was a trend for reversing the lipopolysaccharide-induced decrease in macrophage numbers, but this was not significant (Fig. 3A, left) . Similarly, at both the 3-and 24-h time points, a trend toward inhibiting the lipopolysaccharide-induced increases in lung inflammatory cells was observed for the 100 g/kg dose of CGS-21680 (given half an hour before and 6 h after the challenge), but this did not reach statistical significance (Fig. 3, A and B, left) .
At the 3-h time point, a trend for inhibiting lipopolysaccharide-induced TNF-␣, keratinocyte chemoattractant (KC; murine equivalent of human IL-8), or macrophage inflammatory protein-2 (MIP-2; the murine equivalent of human GRO-␣) release was observed for CGS-21680, although this did not reach statistical significance (Fig. 3A, right) . In contrast, CGS-21680 potently inhibited the lipopolysaccharide-induced elastase release, measured at the 24-h time point, with full inhibition observed at the 100 g/kg dose (Fig. 3B, right) .
At both time points, no mucin could be detected in the bronchoalveolar lavage fluids of the lipopolysaccharide-or PBS-challenged animals.
Effect of CGS-21680 in the lipopolysaccharide/fMLP model of lung neutrophil activation. To study further the inhibitory effect of CGS-21680 on neutrophil activation, animals were sequentially challenged with lipopolysaccharide and fMLP. Animals challenged with lipopolysaccharide only had an increased level of bronchoalveolar lavage fluid elastase when compared with the PBS-challenged group. The bronchoalveolar lavage fluid elastase level was further enhanced in the animals challenged with lipopolysaccharide and fMLP. CGS-21680, given intranasally half an hour before the fMLP challenge, fully inhibited the fMLP-induced increase in elastase levels with a calculated ED 50 of 6 Ϯ 2 g/kg (Fig. 4) .
Effect of CGS-21680 in the cigarette smoke model of lung inflammation.
One day after the last of three daily exposures, cigarette smoke increased the number of bronchoalveolar lavage fluid neutrophils and decreased the macrophage numbers. Results are expressed as means Ϯ SE from 8 mice/group. Budesonide's ED50 values in the acute model were calculated from our previously published work (9). On day 26, mice were either challenged with a 5% ovalbumin solution (OA/OA) or its vehicle PBS (OA/PBS). A control group of sensitized mice was challenged with PBS on days 21-23 and 36 (PBS/PBS). Animals were intranasally treated with CGS-21680 (twice daily), budesonide (once daily), or their vehicle (twice daily), starting half an hour or 1 h before the last challenge for CGS-21680 and budesonide, respectively. Allergen-induced bronchoconstriction and airway reactivity to aerosolized methacholine were measured 4 and 24 h after the last allergen challenge, respectively. Two days after the last challenge, BAL was performed and differential inflammatory cell counts and mucin levels were determined. Significance (*P Ͻ 0.05) is vs. vehicle-treated/ovalbumin-challenged animals (OA/OA). Results are expressed as means Ϯ SE from 8 mice/group. CGS-21680 (10 and 100 g/kg) given intranasally half an hour before and 6 h after the two last smoke exposures inhibited the increase in neutrophil numbers, although this was not significant. The decrease in macrophage numbers was dose dependently reversed by CGS-21680 with a significant reversal observed for the dose of 100 g/kg (Fig. 5) . No neutrophil elastase activity could be detected in the bronchoalveolar lavage fluids of the cigarette smoke or the sham-exposed animals.
DISCUSSION
In this report, we have shown that activation of the A 2A receptor inhibited the inflammatory cell influx in allergendriven models of lung inflammation but did not affect other asthma-like parameters such as airway hyperreactivity, allergen-induced bronchoconstriction, or mucus secretion. On the other hand, in COPD murine models, A 2A receptor activation does not inhibit airway neutrophil influx but reverses the decrease in macrophage numbers and potently inhibits neutrophil activation.
The adenosine A 2A receptor belongs to the seven-transmembrane family of receptors and is associated with the stimulatory G protein, Gs. Thus the A 2A receptor is positively coupled to adenylate cyclase, and its stimulation increases cAMP, activating intracellular pathways known to have anti-inflammatory properties (29) . In addition, the use of A 2A receptor-deficient mice has provided direct and conclusive evidence for a non- 4 . Effect of CGS-21680 on BAL fluid neutrophil elastase activity after lipopolysaccharide/N-formyl-Met-Leu-Phe (LPS/fMLP) challenge. Mice were either challenged with an intranasal application of PBS (50 l) or LPS (0.3 mg/kg). Twenty-four hours after, fMLP (5 mg/kg) or its vehicle (50 l of 1% DMSO in PBS) was applied intranasally, and animals were killed 2 h thereafter. Animals were intranasally treated with 10 or 100 g/kg of CGS-21680 or its vehicle half an hour before the fMLP challenge. BAL was performed, and differential inflammatory cell counts and neutrophil elastase activity in the BAL fluid supernatant was determined. Significance (*P Ͻ 0.05) is vs. LPS-and fMLP-challenged animals treated with compound vehicle (LPS/fMLP). Results are expressed as means Ϯ SE from 8 mice/group. redundant role of this receptor in the downregulation of inflammation in vivo (30) . As such, in models of acute liver inflammation and sepsis, A 2A receptor-deficient mice had dramatically increased tissue damage and a prolonged inflammatory reaction (30) .
Our data in the acute ovalbumin challenge model in the mouse confirmed previously published work that demonstrates that activation of the A 2A receptor leads to a potent inhibition of inflammatory cells infiltrating the rat airways after allergen challenge (15) . The inhibitory effect on inflammatory cell influx was confirmed in a more stringent model of murine asthma (i.e., compound given therapeutically), although a loss of potency for the compound was observed. The mechanism of action for this anti-inflammatory effect still remains to be elucidated, but it has been demonstrated that activation of T cells, which play a crucial role in the recruitment of inflammatory cells into the airways in both human asthma (7) and murine models of allergic inflammation (12) , is suppressed by activation of the A 2A receptor (25) . In addition, activation of mature dendritic cells that play an important role in the initiation and regulation of immune response (23) is also inhibited by activation of the A 2A receptor (34) . Therefore, activation of the A 2A receptor in the pathogenesis of asthma has the potential to not only interfere with an established airway inflammation by inhibiting T cell activation but also to inhibit early inflammatory events, such as antigen presentation by downregulating dendritic cell activation.
Although CGS-21680 is widely used as an A 2A selective agonist, one cannot exclude a possible activation of the A 3 receptor when this compound is given at a high dose. In cell-based assays using transfected human adenosine receptors, we have determined a functional potency for CGS-21680 at the A 2A receptor of 60 nM, a selectivity ratio of ϳ15 against the A 3 receptor, and a selectivity ratio of Ͼ100 for the A 2B and A 1 receptors. However, when extrapolating the human selectivity data to laboratory animals, one has to take into account differences in the pharmacology of the A 3 adenosine receptors from different species (17) . In addition, it is always difficult to extrapolate the receptor selectivity profile of a compound based only on its pharmacological profile in vitro; an in vivo evaluation is always more relevant. In this respect, the anti-inflammatory effect of CGS-21680 in a rat allergen-driven model of lung inflammation has been shown to be fully inhibited by pretreatment with ZM-241385, a specific A 2A antagonist (15) . We did attempt to inhibit the anti-inflammatory effect of CGS-21680 with ZM-241385. Unfortunately, in our hands, when used at a dose of 3 mg/kg in the murine ovalbumin model, adverse events were observed and a meaningful conclusion could not be drawn from this experiment. However, assuming that CGS-21680 is reaching high enough local concentrations within the lung to activate the A 3 receptor, it is very unlikely that it could account for the anti-inflammatory effect observed. Indeed, activation of the A 3 receptor, in a murine model of lung inflammation, has been shown to have a proinflammatory effect (42, 43) .
In the repeated allergen challenge model, animals chronically treated with a high dose of CGS-21680 (100 g/kg) developed a bronchoconstriction. The A 2B and A 3 adenosine receptors have been suggested to be responsible for the adenosine-induced bronchoconstriction in a murine model of allergen-induced lung inflammation (14) . Therefore, a putative activity of CGS-21680 at the murine A 3 receptor, as discussed above, could explain this effect. However, if this was the case, one would have expected to see the same phenomenon in the acute challenge model. Interestingly, a recent study has reported that, when compared with wild-type mice, mice deficient for the A 2A receptor had a higher baseline lung function and a significantly higher dose response to aerosolized methacholine (13) . This suggests that the observed bronchoconstriction in our study could be due to desensitization of the A 2A receptor after chronic treatment with a high dose of CGS-21680.
In the two asthma models presented in this study, CGS-21680 was more than or at least as potent as budesonide in inhibiting airway inflammation. On the other hand, CGS-21680 was ineffective against other asthma-like parameters that were fully inhibited by budesonide (i.e., airway hyperreactivity, allergen-induced bronchoconstriction, and mucus production). Altogether, the results obtained in our murine asthma models would predict that an A 2A agonist therapy in asthma would not be as efficacious as steroids but would still inhibit airway cellular inflammation.
In contrast to the effect seen in the allergen-driven models, CGS-21680 was ineffective in decreasing inflammatory cell influx (e.g., neutrophil) in the lipopolysaccharide and the cigarette smoke models. This result was rather unexpected since in an in vitro system, A 2A activation has been shown to inhibit neutrophil very late antigen-4 expression and thereby diminished neutrophil binding to VCAM-1, an essential primary step for neutrophil migration into tissues (38) . However, after adherence to the endothelium, neutrophils need a chemotactic signal to migrate into the airways. Our data, using the lipopolysaccharide model, show that CGS-21680 treatment does not significantly inhibit the production of such chemotactic signals (TNF-␣, KC, and MIP-2). These cytokines/chemokines have been shown to play a crucial role in the neutrophil recruitment following either lipopolysaccharide (19, 21, 33) or cigarette smoke challenge (4, 35, 39) in mice and rats. It is Fig. 5 . Effect of CGS-21680 on BAL fluid cellular inflammation after cigarette smoke exposure. Mice were exposed to either air or cigarette smoke (smoke) for 3 consecutive days. Twenty-four hours after the last exposure, animals were killed and BAL was performed. From the 2nd day of exposure, animals were intranasally treated with 10 or 100 g/kg of CGS-21680 or its vehicle 1 ⁄2 h before and 4 h after the smoke exposure. Significance (*P Ͻ 0.05) is vs. smoke-exposed animals treated with compound vehicle. Results are expressed as means Ϯ SE from 8 mice/group. therefore not surprising that CGS-21680 was unable to inhibit the neutrophil influx in our murine models of COPD.
Regardless of the lack of effect on inflammatory cell influx, CGS-21680 potently inhibited neutrophil activation, as measured by inhibition of the neutrophil elastase in two different models. This observation is in line with the published literature demonstrating a potent effect of adenosine A 2A agonists on neutrophil activation in vitro (1, 40) . In addition, although not significant, a clear trend for inhibition of the lipopolysaccharide-induced KC and MIP-2 release was observed. This could reflect the inhibitory action of CGS-21680 on neutrophil activation. Indeed, upon activation with lipopolysaccharide, the neutrophil has been shown to be able to release IL-8 (22, 32) . Although indirect, our data also indicate an inhibitory effect of CGS-21680 on macrophage activation. In the cigarette smoke exposure model, the decrease in bronchoalveolar lavage fluid macrophage numbers was reversed by the compound. This decrease in macrophages has been reported previously following both cigarette smoke (35) and lipopolysaccharide (20) exposure in rats and has been attributed to macrophage activation resulting in an increased adherence to the lung matrix protein (27, 35) .
Together, our results suggest that therapies aimed at activating the A 2A receptor could be beneficial in airway diseases such as asthma and COPD. Despite the fact that the antiinflammatory activity of CGS-21680 was restricted to the inhibition of inflammatory cell infiltration in our asthma models, one can still envisage using such a therapy in patients poorly controlled by inhaled steroids. Indeed, the fundamental differences in the mechanism of action for an A 2A agonist and an inhaled steroid might lead to a beneficial effect in this patient category. The potent inhibition of neutrophil and macrophage activation seen in our COPD models also suggests that A 2A receptor agonists would have a beneficial effect on patients with COPD. However, important issues would need to be overcome before such a therapy would be available. The A 2A receptor has a wide tissular distribution and is responsible for a variety of systemic and central effects (18) . Therefore, it is likely that a selective action within the lung will be necessary to avoid unacceptable side effects.
